| Item | Amount | Y/Y |
|---|---|---|
| Revenue | ¥17.62B | +8.1% |
| Gross profit | ¥3.78B | — |
| Operating income | ¥1.75B | — |
| Net income | ¥1.59B | -31.3% |
| Gross margin | 21.5% | Net margin 9.0% |
| Revenue Q/Q | -1.1% | — |
The filing did not disclose a revenue breakdown for this period.
| Item | Amount | % of revenue |
|---|---|---|
| Cost of revenue | ¥13.83B | 78.5% |
| R&D | ¥1.30B | 7.4% |
| SG&A | ¥0.77B | 4.4% |
| Tax & other | ¥0.15B | 0.9% |
The Sankey chart shows how revenue splits into cost of revenue, R&D and SG&A, and what remains as profit — clean visuals for research decks and social posts.
特锐德 ・ 神州泰岳 ・ 乐普医疗 ・ 南风股份 ・ 探路者 ・ 莱美药业 ・ 汉威科技 ・ 天海防务 ・ 安科生物 ・ ST豆神 ・ 鼎汉技术 ・ 华测检测
Source: Eastmoney · This page shows public filing data only, not investment advice. · Browse all companies